Dr Vahitha Abdul Salam
Lecturer
Centre for Cardiovascular Medicine and Device Innovation
Queen Mary University of London
Queen Mary University of London
Research
Vascular dysfunction, Proteomics, Drug Discovery, Chloride intracellular channel protein, Pulmonary hypertension, Environmental Toxicology
Interests
My research involves using multidisciplinary approaches to discover and develop drugs that affect vascular health. For example, I am currently developing inhibitors of chloride intracellular channel proteins as a target for cardiovascular diseases and cancer. In addition, I plan to establish vasculature-on-chip models to validate such inhibitors' use and study the interaction of environmental toxicants on vascular health.Publications
2023
Alzaydi MM, Abdul-Salam VB, Whitwell HJ, Russomanno G, Glynos A, Capece D, Szabadkai G, Wilkins MR and Wojciak-Stothard B (2023). Intracellular Chloride Channels Regulate Endothelial Metabolic Reprogramming in Pulmonary Arterial Hypertension. American Thoracic Society American Journal of Respiratory Cell and Molecular Biology vol. 68, (1) 103-115.
2022
Olotu F, Medina-Carmona E, Serrano-Sanchez A, Ossa F, El-Hamdaoui A, Bishop ÖT, Ortega-Roldan JL and Abdul-Salam VB (2022). Structure-based discovery and in vitro validation of inhibitors of chloride intracellular channel 4 protein. Elsevier Computational and Structural Biotechnology Journal vol. 21, 688-701.
Varela L, Hendry AC, Cassar J, Martin-Escolano R, Cantoni D, Ossa F, Edwards JC, Abdul-Salam V and Ortega-Roldan JL (2022). A Zn2+-triggered two-step mechanism of CLIC1 membrane insertion and activation into chloride channels. The Company of Biologists Journal of Cell Science vol. 135, (15)
2021
Shaikh FS, Aldhafferi N, Buker A, Alqahtani A, Dey S, Abdulhamid S, AlBuhairi DAM, Alkabour RSA, Atiyah WSO, Chrouf SB, Alshehri A, Olatunji SO, Almuhaideb AM, Alshahrani MS, AlMunsour Y and Abdul-Salam VB (2021). Comorbidities and Risk Factors for Severe Outcomes in COVID-19 Patients in Saudi Arabia: A Retrospective Cohort Study. Taylor & Francis Journal of Multidisciplinary Healthcare vol. 14, 2169-2183.
Medvedev R, Sanchez-Alonso JL, Alvarez-Laviada A, Rossi S, Dries E, Schorn T, Abdul-Salam VB, Trayanova N, Wojciak-Stothard B, Miragoli M, Faggian G and Gorelik J (2021). Nanoscale Study of Calcium Handling Remodeling in Right Ventricular Cardiomyocytes Following Pulmonary Hypertension. Hypertension vol. 77, (2) 605-616.
2020
Russomanno G, Jo KB, Abdul-Salam VB, Morgan C, Endruschat J, Schaeper U, Osman AH, Alzaydi MM, Wilkins MR and Wojciak-Stothard B (2020). miR-150-PTPMT1-cardiolipin signaling in pulmonary arterial hypertension. Elsevier Molecular Therapy - Nucleic Acids vol. 23, 142-153.
Sindi HA, Russomanno G, Satta S, Abdul-Salam VB, Jo KB, Qazi-Chaudhry B, Ainscough AJ, Szulcek R, Bogaard HJ, Morgan CC, Pullamsetti SS, Alzaydi MM, Rhodes CJ, Piva R, Eichstaedt CA, Grünig E, Wilkins MR and Wojciak-Stothard B (2020). Author Correction: Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. Nat Commun vol. 11, (1) 3300-3300.
Russomanno G, Jo KB, Abdul Salam V, Morgan C, Alzaydi M, Wilkins M and Wojciak-Stothard B (2020). 1 Role of endothelial microRNA-150 in pulmonary arterial hypertension. Biorxiv
Sindi HA, Russomanno G, Satta S, Abdul-Salam VB, Jo KB, Qazi-Chaudhry B, Ainscough AJ, Szulcek R, Jan Bogaard H, Morgan CC, Pullamsetti SS, Alzaydi MM, Rhodes CJ, Piva R, Eichstaedt CA, Grünig E, Wilkins MR and Wojciak-Stothard B (2020). Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. Springer Nature Nature Communications vol. 11, (1)
2018
Abdul-Salam VB, Russomanno G, Chien-Nien C, Mahomed AS, Yates LA, Wilkins MR, Zhao L, Gierula M, Dubois O, Schaeper U, Endruschat J and Wojciak-Stothard B (2018). CLIC4/Arf6 Pathway A New Lead in BMPRII Inhibition in Pulmonary Hypertension. Circ Res vol. 124, (1) 52-65.
Edwards RJ, Pyzio M, Gierula M, Turner CE, Abdul-Salam VB and Sriskandan S (2018). Proteomic analysis at the sites of clinical infection with invasive Streptococcus pyogenes. Springer Nature Scientific Reports vol. 8, (1)
2017
Duluc L, Ahmetaj-Shala B, Mitchell J, Abdul-Salam VB, Mahomed AS, Aldabbous L, Oliver E, Iannone L, Dubois OD, Storck EM, Tate EW, Zhao L, Wilkins MR and Wojciak-Stothard B (2017). Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. Oxford University Press (Oup) Cardiovascular Research vol. 113, (3) 276-287.
2016
Aldabbous L, Abdul-Salam V, McKinnon T, Duluc L, Pepke-Zaba J, Southwood M, Ainscough AJ, Hadinnapola C, Wilkins MR, Toshner M and Wojciak-Stothard B (2016). Neutrophil Extracellular Traps Promote Angiogenesis. Wolters Kluwer Arteriosclerosis Thrombosis and Vascular Biology vol. 36, (10) 2078-2087.
2014
Wojciak-Stothard B, Abdul-Salam VB, Lao KH, Tsang H, Irwin DC, Lisk C, Loomis Z, Stenmark KR, Edwards JC, Yuspa SH, Howard LS, Edwards RJ, Rhodes CJ, Gibbs JSR, Wharton J, Zhao L and Wilkins MR (2014). Aberrant Chloride Intracellular Channel 4 Expression Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. Wolters Kluwer Circulation vol. 129, (17) 1770-1780.
2010
Abdul-Salam VB, Wharton J, Cupitt J, Berryman M, Edwards RJ and Wilkins MR (2010). Proteomic Analysis of Lung Tissues From Patients With Pulmonary Arterial Hypertension. Wolters Kluwer Circulation vol. 122, (20) 2058-2067.
Paratz E and Abdul Salam V (2010). Investigation of lactate dehydrogenase isoenzymes as candidate biomarkers of idiopathic pulmonary arterial hypertension. Australian Medical Student Journal vol. 1, 16-20.
Abdul-Salam VB, Ramrakha P, Krishnan U, Owen DR, Shalhoub J, Davies AH, Tang TY, Gillard JH, Boyle JJ, Wilkins MR and Edwards RJ (2010). Identification and Assessment of Plasma Lysozyme as a Putative Biomarker of Atherosclerosis. Wolters Kluwer Arteriosclerosis Thrombosis and Vascular Biology vol. 30, (5) 1027-1033.
2006
Abdul‐Salam VB, Paul GA, Ali JO, Gibbs SR, Rahman D, Taylor GW, Wilkins MR and Edwards RJ (2006). Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Wiley Proteomics vol. 6, (7) 2286-2294.
Grants
KTP with WRc: Risk Assessment of Microplastics in Human Health (PI: Vahitha Abdul Salam)
Vahitha Abdul Salam and Kate Spencer
£194,212 Innovate UK (01-08-2023 - 31-07-2025)
Vahitha Abdul Salam and Kate Spencer
£194,212 Innovate UK (01-08-2023 - 31-07-2025)
Water Research Centre Pump Priming Award
Vahitha Abdul Salam
£20,000 Water Research Centre (01-04-2022 - 31-03-2023)
Vahitha Abdul Salam
£20,000 Water Research Centre (01-04-2022 - 31-03-2023)